Emerging Cancer Therapeutics is a quarterly, hard cover, periodical that is designed to provide an up-to-date review of a dedicated emerging cancer therapy.
Table of contents
- Disease Biomarkers in Gastrointestinal Malignancies
- Disease Markers
- Supplemental Content
- Promising therapeutics of gastrointestinal cancers in clinical trials.
Didn't get the message?
Disease Biomarkers in Gastrointestinal Malignancies
Add to My Bibliography. Generate a file for use with external citation management software. Abstract Many novel therapeutics are being developed for patients with cancers along the gastrointestinal GI tract. Images from this publication. See all images 1 Free text. To get the free app, enter your mobile phone number.
Disease Markers
Would you like to tell us about a lower price? Learn more about Amazon Prime.
Gastrointestinal Malignancies Gastrointestinal GI cancers are common diseases worldwide. Read more Read less. Kindle Cloud Reader Read instantly in your browser.
- Melonhead and the Big Stink.
- Promising therapeutics of gastrointestinal cancers in clinical trials. - PubMed - NCBI.
- CPcom | 商務印書館門市網站!
- !
- ?
- Coyotes Mate (Breed Book 18).
Product details File Size: Demos Medical; 1 edition April 6, Publication Date: April 6, Sold by: Related Video Shorts 0 Upload your video. Customer reviews There are no customer reviews yet. Share your thoughts with other customers. Write a customer review. Amazon Giveaway allows you to run promotional giveaways in order to create buzz, reward your audience, and attract new followers and customers.
Learn more about Amazon Giveaway. Set up a giveaway. Feedback If you need help or have a question for Customer Service, contact us.
Supplemental Content
Would you like to report poor quality or formatting in this book? Click here Would you like to report this content as inappropriate? Click here Do you believe that this item violates a copyright? Lower GI cancers are among the top three most frequent cancers in the United States and many western countries while upper GI cancers rank as the most prevalent type in many Asian countries, especially in central and eastern Asia. GI cancers are usually diagnosed in more advanced stages and in the absence of effective early diagnostic tools and therapeutic modalities, the survival rates are generally disappointingly low.
- Related Video Shorts (0)?
- Soldier Boys.
- Lemons and Running?
- Product details?
- ;
- Kiss Chase!
- ;
Considering the high mortality rate, tremendous effort has been directed to address the urgent need for discovery of effective early diagnostic tools, efficient therapeutic targets, and treatment monitoring markers for GI malignancies. Biomarkers are one of these favorite tools with several potential applications in various aspects of clinical management of cancers.
A plethora of biomarkers has been studied in GI cancers, of which only a handful have found their way from bench to bed. Nonetheless, there is a growing list of emerging markers with promising clinical results that need to be validated for routine clinical applications and current data are insufficient to recommend them as part of the clinical guidelines.
The current special issue tackles this important area of cancer research.
- Hypertension in the Elderly: Pocketbook!
- The Urban Nomad: Paris.
- An Exhaustively Cross-Referenced Bible - Book 1 - Genesis 1 – Genesis 20!
- Prodigy - Novella for the Christian Spirit.
In this issue, S. In addition, high BST2 expression in CRC tissue, as assessed by immunohistochemistry, was associated with poorer 5-year survival.
Promising therapeutics of gastrointestinal cancers in clinical trials.
BST2 has also been under investigation as a potential target for immunotherapy for over a decade [ 7 ]. In fact, a humanized monoclonal antibody targeting BST2 has been tested in Phase 1 trial of multiple myeloma MM but the response rate was low [ 8 ].
However, given its detection in the plasma, future studies should also examine BST2 as a novel biomarker to noninvasively monitor therapeutic response. In another study, T.